Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | GPR39 | O43194 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144139 | 0.92 | PGR (0.45) | PGRAR | |
| SCHEMBL4140744 | 0.77 | AR (0.42) | EGFRPGRALDH1A1KDM4EMEN1 | |
| SCHEMBL4150714 | 0.76 | PGR (0.40) | EGFRPGRAR | |
| SCHEMBL4153668 | 0.68 | AR (0.39) | PGRARPLK1 | |
| SCHEMBL1379836 | 0.68 | AR (0.40) | PGRAR | |
| SCHEMBL4150044 | 0.65 | PIEZO1 (0.41) | PGRALDH1A1MEN1KMT2AAR | |
| SCHEMBL17663311 | 0.65 | ALDH1A1 (0.54) | EGFRALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1377245 | 0.65 | AR (0.36) | PGRNPC1RAB9AAR | |
| SCHEMBL1377403 | 0.64 | KDM1A (0.38) | PGRNPC1RAB9AAR | |
| SCHEMBL4145337 | 0.64 | AR (0.41) | PGRALDH1A1KDM4EAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | claimed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170907-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1888512-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170907-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | EGFR 885/4885PGR 27/4885ALDH1A1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.